Inhibition of IL-8/CXCR2 may disrupt multiple immunosuppressive pathways simultaneously, providing a rationale for therapeutic targeting of the CXCR2 axis in advanced prostate cancer. The gene discussed is CXCR2; the disease is prostate carcinoma.